Jamie Dananberg - 31 Mar 2023 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Reporting relationship: Chief Medical Officer
Issuer ticker: UBX
Reported as of: 31 Mar 2023
Net transaction value: -$714
SEC form: 4
Accepted by SEC: 03 Apr 2023, 16:51:04 UTC
Prior SEC filing: 15 Mar 2023
Next SEC filing: 02 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Alexander Nguyen, Attorney-in-Fact for Jamie Dananberg

Key filing fact

Jamie Dananberg filed Form 4 for Unity Biotechnology, Inc. (UBX) on 03 Apr 2023.

Key facts

This page summarizes Jamie Dananberg's Form 4 filing for Unity Biotechnology, Inc. (UBX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Apr 2023, 16:51.

Change

Previous filing in this sequence was filed on 15 Mar 2023.
Current net transaction value: -$714.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UBX transaction

Common Stock, $0.0001 par value

Sale

Transaction value: $714
Shares: -420
Change %: -0.66%
Price: $1.70
Shares after: 62,817
Date: 31 Mar 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Footnote F2

Includes Restricted Stock Units which vest over time measured from the grant date.